Cartalax

Cartalax is commonly mapped to the ultrashort AED tripeptide. The defensible public literature is narrow and mostly mechanistic: studies describe AED among short peptides that can influence aging-associated markers in cultured cells, human mesenchymal stem-cell aging cultures, and modeled peptide-DNA interactions. These sources are useful for explaining why Cartalax appears in peptide bioregulator research, but they do not establish cartilage repair, joint outcomes, human anti-aging effects, dosing, or safety. Content for this page should therefore frame Cartalax/AED as an experimental short-peptide bioregulator candidate with laboratory gene-expression and cell-aging data, not as a proven joint, cartilage, or longevity therapy.

Cell-Aging Models

AED was evaluated in aged human fibroblast cultures and human mesenchymal stem-cell aging cultures for effects on proliferation, regeneration, apoptosis-associated markers, and aging-related gene expression ^[1][3].

Gene-Expression Hypotheses

Modeling and review literature place AED among short peptides proposed to bind DNA motifs and alter gene expression, but this is mechanistic research rather than clinical evidence ^[2][4].

Evidence Boundary

Cartilage-specific and human outcome claims are not supported by the cleared literature. Cartalax should be presented as a research peptide only ^[4].

No Clinical Safety Dataset

No FDA/EMA-style label, phase 1 safety study, or controlled human clinical trial was located for Cartalax/AED ^[4].

Laboratory Evidence Limits

Available evidence is mainly in vitro, cell-aging, or modeling work. Dosing, pharmacokinetics, long-term toxicity, reproductive safety, immunogenicity, and drug-interaction risks remain undefined ^[1][2][3].